American Bio Medica Corporation
ABMC
$0.00
$0.000.00%
OTC PK
| 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | 03/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -53.28% | -67.19% | -65.96% | -65.03% | -37.99% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -53.28% | -67.19% | -65.96% | -65.03% | -37.99% |
| Cost of Revenue | -72.14% | -20.47% | -49.18% | -34.35% | -29.93% |
| Gross Profit | 164.29% | -213.82% | -104.86% | -153.68% | -73.33% |
| SG&A Expenses | -23.44% | -28.79% | -37.23% | -28.69% | -43.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -44.87% | -23.53% | -42.42% | -31.18% | -36.56% |
| Operating Income | 35.95% | -76.58% | -28.43% | -42.21% | 34.97% |
| Income Before Tax | 596.31% | 2.46% | -147.36% | -63.79% | 31.83% |
| Income Tax Expenses | -- | -- | -- | 0.00% | -- |
| Earnings from Continuing Operations | 596.31% | 2.46% | -147.36% | -63.27% | 31.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 596.31% | 2.46% | -147.36% | -63.27% | 31.83% |
| EBIT | 35.95% | -76.58% | -28.43% | -42.21% | 34.97% |
| EBITDA | 35.85% | -83.09% | -33.69% | -47.79% | 35.23% |
| EPS Basic | 594.94% | -8.20% | -143.05% | -38.33% | 44.76% |
| Normalized Basic EPS | 40.00% | -57.69% | -187.23% | -40.54% | 43.82% |
| EPS Diluted | 594.94% | -54.10% | -166.23% | 0.00% | 44.76% |
| Normalized Diluted EPS | 40.00% | -57.69% | -187.23% | -40.54% | 43.82% |
| Average Basic Shares Outstanding | 0.69% | -9.59% | 9.26% | 17.45% | 22.93% |
| Average Diluted Shares Outstanding | 0.69% | -9.59% | 9.26% | 17.45% | 22.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |